Antihypertensive Treatment of Cerebral Hemorrhage (ATACH-II)
An estimated 37,000 to 52,000 people in the United States have intracerebral hemorrhage (ICH) every year. Elevated blood pressure (BP) is observed in 46 to 75 percent of patients with ICH, and a variety of BP protocols are in place for treatment but lack appropriate evidence. Hematoma expansion is a common and important cause of poor outcome and elevated BP may predispose to hematoma expansion. Experimental clinical studies suggest reduction of elevated BP may be tolerated and feasible.
ATACH-II is a phase III, randomized, multicenter, concurrently controlled, parallel arms design clinical trial examining blood pressure reduction for hypertension in acute ICH. It will determine the therapeutic benefit of intensive SBP treatment using IV nicardipine (SBP≤140) compared with standard SBP treatment (SBP≤180) in reducing the proportion of patients with death and disability in subjects with ICH treated within 3.5 hours.
You may be eligible to participate in this study if you:
- Are an adult over 18 years of age
- Exhibit clinical signs consistent with diagnosis of stroke, including impairment of language, motor function, cognition, and/or gaze, vision or neglect
- Can receive IV Nicardipine within 3.5 hours of symptom onset
- Can be randomized within 3.5 hours of symptom onset
You will be excluded from this study if you:
- Have ICH due to previously known neoplasms, AVM or aneurysms
- Have intracerebral hematoma considered to be related to trauma
- Are to receive immediate surgical evacuation
This is a partial list of eligibility requirements. To inquire about your eligibility, please call the contact number provided. If you wish to inquire via email, please include the title of the study in your message.